H1 2025 Results

Summary by AI BETAClose X

Diaceutics PLC reported strong H1 2025 results, with revenue reaching £14.6 million, a 22% increase on a constant currency basis, representing a 3-year CAGR of 25%. The company's Annual Recurring Revenue (ARR) grew by 16% to £16.4 million, with recurring revenue now accounting for 61% of total H1 revenues. Diaceutics' order book stands at £31.7 million, with £9.0 million already contracted for H2 2025 delivery. Adjusted EBITDA was £0.1 million, putting the company on track for full-year profitability. The company reported a strong balance sheet with no debt and cash reserves of £10.4 million. The number of customer therapeutic brands Diaceutics is working with increased by 17%. A new enterprise-wide agreement was signed, bringing the total to eight, representing £10.1 million in ARR.

Disclaimer*

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings